Tempus (Pharacogenetic Testing)
Tempus (Pharacogenetic Testing) explained
Tempus (Pharacogenetic Testing) evaluates genetic variants that may influence how you metabolize or respond to certain psychiatric medications.
Some panels have FDA‑cleared components; overall offering typically LDT under CLIATempus (Pharacogenetic Testing) helps treat
• Pharmacogenetic guidance for medication selection
• Metabolism (CYP450) and transport variants
• Side‑effect risk discussions
additional medications
• Related clinical evaluation and history
• Repeat testing to confirm abnormal results
• Additional targeted labs as recommended
medication risks
• Genetic privacy and potential insurance/employment implications
• Limited clinical actionability for some markers
side effects
• Emotional impact of unexpected findings
FAQs
Q: Does it replace clinical judgment?A: No—results supplement, not replace, clinician decision‑making.
Q: Guaranteed to improve outcomes?
A: No—evidence varies by drug/gene; utility depends on case.
Q: Privacy/insurance?
A: Genetic data has implications; review policies and GINA protections.
Q: Sample?
A: Usually cheek swab/saliva.
Q: Turnaround?
A: Typically 1–3 weeks.